A process for preparing a tin-containing zeolitic material having framework type BEA, comprising providing an aqueous synthesis mixture comprising a boron source, a silicon source, and a BEA structure directing agent; subjecting the synthesis mixture provided in to hydrothermal pre-crystallization conditions; adding the tin source to the obtained mixture; subjecting the obtained aqueous synthesis mixture to hydrothermal crystallization conditions, obtaining a tin-containing zeolitic material having framework type BEA comprised in its mother liquor.

A process for preparing a tin-containing zeolitic material having framework type BEA, comprising providing an aqueous synthesis mixture comprising a boron source, a silicon source, and a BEA structure directing agent; subjecting the synthesis mixture provided in to hydrothermal pre-crystallization conditions; adding the tin source to the obtained mixture; subjecting the obtained aqueous synthesis mixture to hydrothermal crystallization conditions, obtaining a tin-containing zeolitic material having framework type BEA comprised in its mother liquor.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.

The present invention discloses a method for preparing -caprolactone. The method comprises the steps of: adding cyclohexanone, a co-oxidant and a certain amount of catalyst into a certain amount of organic solvent, using molecular oxygen as an oxidant, implementing a reaction with stirring for 0.1 to 24 hours under a pressure of 0.1 to 2 MPa and at a temperature of 60 C. to 100 C., wherein the co-oxidant is acrolein, and the catalyst is a carbon material. The present invention has the advantages of high-efficiency co-oxidant, easily available and recovered catalyst, environmental-friendly oxidant, simple operation and low cost.

The present invention discloses a method for preparing -caprolactone. The method comprises the steps of: adding cyclohexanone, a co-oxidant and a certain amount of catalyst into a certain amount of organic solvent, using molecular oxygen as an oxidant, implementing a reaction with stirring for 0.1 to 24 hours under a pressure of 0.1 to 2 MPa and at a temperature of 60 C. to 100 C., wherein the co-oxidant is acrolein, and the catalyst is a carbon material. The present invention has the advantages of high-efficiency co-oxidant, easily available and recovered catalyst, environmental-friendly oxidant, simple operation and low cost.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Synthesizing an alkyl-caprolactone includes hydrogenating an alkyl-phenol to yield a first mixture comprising an alkyl-cyclohexanone and an alkyl-cyclohexanol; separating the alkyl-cyclohexanone from the first mixture to yield a first portion of a purified alkyl-cyclohexanone; oxidizing the first portion of the purified alkyl-cyclohexanone to yield a second mixture comprising an alkyl-caprolactone, the alkyl-cyclohexanone, and the alkyl-cyclohexanol; separating the alkyl-caprolactone from the second mixture to yield a third mixture comprising the alkyl-cyclohexanone and the alkyl-cyclohexanol; combining the third mixture and the first mixture in to yield a fourth mixture; separating the alkyl-cyclohexanone from the fourth mixture to yield a second portion of the purified alkyl-cyclohexanone; oxidizing the second portion of the purified alkyl-cyclohexanone to yield a fifth mixture comprising the alkyl-caprolactone, the alkyl-cyclohexanone, and the alkyl-cyclohexanol; separating the alkyl-caprolactone from the fifth mixture; and combining the alkyl-caprolactone from the fifth mixture with the alkyl-caprolactone from the second mixture.

Synthesizing an alkyl-caprolactone includes hydrogenating an alkyl-phenol to yield a first mixture comprising an alkyl-cyclohexanone and an alkyl-cyclohexanol; separating the alkyl-cyclohexanone from the first mixture to yield a first portion of a purified alkyl-cyclohexanone; oxidizing the first portion of the purified alkyl-cyclohexanone to yield a second mixture comprising an alkyl-caprolactone, the alkyl-cyclohexanone, and the alkyl-cyclohexanol; separating the alkyl-caprolactone from the second mixture to yield a third mixture comprising the alkyl-cyclohexanone and the alkyl-cyclohexanol; combining the third mixture and the first mixture in to yield a fourth mixture; separating the alkyl-cyclohexanone from the fourth mixture to yield a second portion of the purified alkyl-cyclohexanone; oxidizing the second portion of the purified alkyl-cyclohexanone to yield a fifth mixture comprising the alkyl-caprolactone, the alkyl-cyclohexanone, and the alkyl-cyclohexanol; separating the alkyl-caprolactone from the fifth mixture; and combining the alkyl-caprolactone from the fifth mixture with the alkyl-caprolactone from the second mixture.